Education
About Us
Working with TipRanks
Follow Us
Biosyent Inc (TSE:RX)
:RX
RX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$8.24 - C$12.13
Previous CloseN/A
Volume6.04K
Average Volume (3M)4.61K
Market Cap
C$118.04M
Enterprise ValueC$109.20M
Total Cash (Recent Filing)C$16.83M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)16.4
Beta0.27
Next Earnings
May 23, 2025EPS Estimate
0.15Last Dividend Ex-Date
Feb 28, 2025Dividend Yield1.8%
Share Statistics
EPS (TTM)0.63
Shares Outstanding11,471,121
10 Day Avg. Volume6,618
30 Day Avg. Volume4,610
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)N/A
Price to Sales (P/S)3.74
Price to Cash Flow (P/CF)12.50
P/FCF Ratio12.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.75Price Target Upside13.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Biosyent News
PremiumCompany Announcements
BioSyent to Participate in Planet MicroCap Showcase 2025
PremiumCompany Announcements
BioSyent to Present at LD Micro Investor Conference
PremiumCompany Announcements
FeraMAX® Tops Canadian Iron Supplement Recommendations for Tenth Year
PremiumCompany Announcements
BioSyent Grants Restricted Share Units to Key Personnel
PremiumCompany Announcements
BioSyent Inc. Earnings Call Highlights Record RevenuePremiumCompany Announcements
BioSyent Inc. Achieves Record Growth and Expands Global Reach in 2024
PremiumCompany Announcements
BioSyent Announces Share Repurchase Plan---
Bulls Say, Bears Say
Bulls Say
Asset AcquisitionBioSyent announced the acquisition of the global rights to Tibella (Tibolone) for EUR 2.8M (~$4.24M CAD) from Mithra Pharmaceuticals SA and its subsidiary Novalon SA.
Financial PerformanceBioSyent reported results that exceeded estimates.
Bears Say
Asset QualityNo physical assets such as production plants or employees were acquired.
RevenueThe topline came in a bit below estimates.
---
Options Prices
Currently, No data available
---
Ownership Overview
39.39% Insiders
0.42%
Mutual Funds
<0.01% Other Institutional Investors
60.19% Public Companies and
Individual Investors
RX FAQ
What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$8.24 and its highest was C$12.13 in the past 12 months.
What is Biosyent Inc’s market cap?
Biosyent Inc’s market cap is C$118.04M.
When is Biosyent Inc’s upcoming earnings report date?
Biosyent Inc’s upcoming earnings report date is May 23, 2025 which is in 29 days.
How were Biosyent Inc’s earnings last quarter?
Biosyent Inc released its earnings results on Mar 13, 2025. The company reported C$0.14 earnings per share for the quarter, missing the consensus estimate of C$0.15 by -C$0.01.
Is Biosyent Inc overvalued?
According to Wall Street analysts Biosyent Inc’s price is currently Undervalued.
Does Biosyent Inc pay dividends?
Biosyent Inc pays a Quarterly dividend of C$0.185 which represents an annual dividend yield of 1.8%. See more information on Biosyent Inc dividends here
What is Biosyent Inc’s EPS estimate?
Biosyent Inc’s EPS estimate is 0.15.
How many shares outstanding does Biosyent Inc have?
Biosyent Inc has 11,471,121 shares outstanding.
What happened to Biosyent Inc’s price movement after its last earnings report?
Biosyent Inc reported an EPS of C$0.14 in its last earnings report, missing expectations of C$0.15. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Biosyent Inc?
Currently, no hedge funds are holding shares in TSE:RX
---
Biosyent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$11.75 (13.09% Upside)
C$11.75 (13.09% Upside)
Insider Transactions
Sold Shares
Worth C$34.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.66%
12-Months-Change
Fundamentals
Return on Equity
20.84%
Trailing 12-Months
Asset Growth
-0.41%
Trailing 12-Months
Company Description
Biosyent Inc
Biosyent Inc. (RX) is a Canadian specialty pharmaceutical company that focuses on the development and commercialization of innovative pharmaceutical and healthcare products. The company primarily operates in the sectors of health science and pharmaceuticals, offering a diverse range of prescription and over-the-counter products. Biosyent's core products include pharmaceuticals for the treatment of iron deficiency, women's health, and urology, as well as other therapeutic areas.
---
RX Stock 12 Month Forecast
Average Price Target
C$11.75
▲(13.09% Upside)
Technical Analysis
Best Analysts Covering RX
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+10.71%
reiterated a buy rating last month
Copying David Martin PhD's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +10.71% per trade.
---